Skip to main content
Back
NVCR logo

NovoCure Limited

Data quality: 100%
NVCR
NASDAQ Healthcare Medical - Instruments & Supplies
$11.82
▲ $0.01 (0.08%)
Mkt Cap: 1.35B
Day Range
$11.63 $12.19
52-Week Range
$9.82 $20.06
Volume
1,263,901
50D / 200D Avg
$12.55 / $13.35
Prev Close
$11.81

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -9.9 0.4
P/B 4.0 2.9
ROE % -38.9 3.8
Net Margin % -20.8 3.9
Rev Growth 5Y % 5.2 10.0
D/E 0.9 0.2

Analyst Price Target

Hold
$33.50 +183.4%
Low: $20.00 High: $47.00
Forward EPS
-$1.51
Est. Revenue
690 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $4.79
$4.49 – $5.35
1.8 B 1
FY2029 $2.45
$2.30 – $2.73
1.5 B 1
FY2028 -$0.42
-$0.50 – -$0.37
920 M 3

Key Takeaways

Revenue grew 5.20% annually over 5 years — modest growth
Negative free cash flow of -75.68M
PEG of 0.49 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.08%
Capital efficient — spends only 4.07% of revenue on capex

Growth

Revenue Growth (5Y)
5.20%
Revenue (1Y)8.28%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-38.89%
ROIC-18.30%
Net Margin-20.79%
Op. Margin-23.47%

Safety

Debt / Equity
0.85
Current Ratio2.90
Interest Coverage0.00

Valuation

P/E Ratio
-9.87
P/B Ratio3.95
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.28% Revenue Growth (3Y) 13.43%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5.20% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 655.35M Net Income (TTM) -136.23M
ROE -38.89% ROA -16.94%
Gross Margin 74.54% Operating Margin -23.47%
Net Margin -20.79% Free Cash Flow (TTM) -75.68M
ROIC -18.30% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.85 Current Ratio 2.90
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -9.87 P/B Ratio 3.95
P/S Ratio 2.05 PEG Ratio 0.49
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.35B Enterprise Value 1.53B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 655.35M 605.22M 509.34M 537.84M 535.03M
Net Income -136.23M -168.63M -207.04M -92.53M -58.35M
EPS (Diluted) -1.22 -1.56 -1.95 -0.88 -0.56
Gross Profit 488.47M 468.04M 381.06M 422.97M 420.15M
Operating Income -153.80M -170.50M -232.87M -89.52M -44.33M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 804.33M 1.24B 1.15B 1.19B 1.14B
Total Liabilities 463.86M 880.61M 783.63M 750.48M 729.00M
Shareholders' Equity 340.47M 360.18M 362.50M 441.17M 410.49M
Total Debt 290.00M 683.35M 596.24M 584.27M 581.90M
Cash & Equivalents 103.39M 163.77M 240.82M 115.33M 209.61M
Current Assets 646.73M 1.11B 1.03B 1.11B 1.07B
Current Liabilities 223.23M 756.38M 179.12M 158.78M 142.60M